Psychedelic medicine: A review of clinical research

The national US non-profit organisation 'BrainFutures' has just published an excellent free 164-page review of clinical research on the use of psychedelics for mental health and substance use disorders. A member of the BrainFutures team is reported as saying: "The paper takes a sober look at the clinical research to date and makes recommendations for adoption of some of these compounds as mainstream treatments for conditions like PTSD and treatment-resistant depression (once approved by the FDA). Our research looks at seven different psychedelics (psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline) and categorizes the clinical evidence for each by condition (depression, anxiety, opioid use disorder, etc.) We believe this is the most comprehensive summary of research on psychedelics as a class that currently exists. We think it will be a fantastic advocacy tool for companies, organizations, and advocates working in this space as they continue to make the case for psychedelics."

For more psychedelic news and research, visit the psychedelic health professional network homepage.